/LXRX

Lexicon Pharmaceuticals Inc

LXRX

$2.00USD↓-0.99%-0.02 today

MARKET CAP

889.9M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$2 – $2

52W RANGE

$1

$3

AI Summary

Stalk

Sell NowMedium

The stock has lost intermediate EMA control with 9/20 EMAs crossing below the 50-day SMA and price closing decisively underneath, indicating structural repair to the downside. Price trading beneath converged EMAs with flat to downward tilt and neutral momentum signals confirms a bearish medium-term bias. Short-term timing is unfavorable for new longs, and the tradable side is bearish. Engagement should occur on rallies into the $2.30–$2.35 resistance zone at the EMA cluster, using rejection setups.

↑JACC: Heart Failure study shows sotagliflozin efficacy at low systolic BP
↑Received $10M milestone payment from Novo Nordisk for LX9851
↓Negative earnings yield (-0.11) and weak profitability raise concerns

Full analysis →

Buying

4

institutions

Selling

6

institutions

New Positions

1

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕	Action↕	Shares Held↕	Value↓	Change↕	Chg %↕	Weight↕
BI Blackrock, Inc. Q2 2026	BUY	17.35 M	41.64 M	+14.03 M	+703.4%	0.00%
PA Point72 Asset Management, L.P. Q2 2026	BUY	8.25 M	19.80 M	+436.72 K	+62.4%	0.02%
CA Citadel Advisors LLC Q2 2026	BUY	1.99 M	4.77 M	+301.08 K	+81.3%	0.00%
MM Millennium Management LLC Q2 2026	SELL	1.13 M	2.72 M	+-3.81 M	-64.7%	0.00%
RT Renaissance Technologies LLC Q2 2026	SELL	1.13 M	2.70 M	+-473.50 K	+8.3%	0.00%
JC Jpmorgan Chase & Co Q2 2026	BUYNEW	109.84 K	289.98 K	+109.84 K	+0.0%	0.00%
AC Aqr Capital Management LLC Q2 2026	SELL	75.23 K	180.55 K	+-21.00 K	+20.3%	0.00%
RC Rockefeller Capital Management L.P. Q2 2026	SELL	300.00	720.00	+-35.00	+37.7%	0.00%
BH Brevan Howard Capital Management LP Q2 2026	SELL	0.00	0.00	+-160.50 K	-100.0%	0.00%
MG Man Group Plc Q2 2026	SELL	0.00	0.00	+-108.81 K	-100.0%	0.00%